ArticleInternational journal of cancer2012
Health and economic impact of HPV 16/18 vaccination and cervical cancer screening in Eastern Africa.
Article in International journal of cancer, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 6 syntheses or guidelines pooled it, 102 citations in OpenAlex.
- A systematic review of economic evaluations of cervical cancer screening methods.Systematic reviews · 2022Pooled it
- Economic evaluation of human papillomavirus vaccination in the Global South: a systematic review.International journal of public health · 2020Pooled it
- Challenges in Cost-Effectiveness Analysis Modelling of HPV Vaccines in Low- and Middle-Income Countries: A Systematic Review and Practice Recommendations.PharmacoEconomics · 2017Pooled it
- Cervical cancer prevention and treatment research in Africa: a systematic review from a public health perspective.BMC women's health · 2016Pooled it
- Systematic review of model-based cervical screening evaluations.BMC cancer · 2015Pooled it
- Pooled it
- Financing of Human Papillomavirus Vaccination in Africa: A Scoping Review.Health science reports · 2026Review
- Supply, demand and use of economic evidence in vaccine policymaking in Africa: A scoping review.PLOS global public health · 2026Article
- Review
- Cost-effectiveness of approaches to cervical cancer screening in Malawi: comparison of frequencies, lesion treatment techniques, and risk-stratified approaches.BMC health services research · 2024Article
- Human papillomavirus genotype distribution patterns in Zimbabwe; is the bivalent vaccine sufficient?Intervirology · 2024Review
- HIV status and knowledge of cervical cancer among women in Ghana.BMC women's health · 2024Article
- High-risk human papillomavirus genotype distribution among women living with HIV; implication for cervical cancer prevention in a resource limited setting.Infectious agents and cancer · 2023Article
- Human papillomavirus vaccination at the national and provincial levels in China: a cost-effectiveness analysis using the PRIME model.BMC public health · 2022Article
- Lives saved with vaccination for 10 pathogens across 112 countries in a pre-COVID-19 world.eLife · 2021Article
- Screen, Notify, See, and Treat: Initial Results of Cervical Cancer Screening and Treatment in Rwanda.JCO global oncology · 2021Article
- The missing link in Kenya's universal health coverage experiment: a preventive and promotive approach to SRHR.Sexual and reproductive health matters · 2020Article
- HPV-FRAME: A consensus statement and quality framework for modelled evaluations of HPV-related cancer control.Papillomavirus research (Amsterdam, Netherlands) · 2019Article
- Impact of Initiating Screening Programs on Referral and Management of Cervical Cancer in Tanzania.Journal of global oncology · 2019Article
- Development and application of a framework to estimate health care costs in China: The cervical cancer example.PloS one · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 2 countries.
Funding
Abstract
Eastern Africa has the world's highest cervical cancer incidence and mortality rates. We used epidemiologic data from Kenya, Mozambique, Tanzania, Uganda, and Zimbabwe to develop models of HPV-related infection and disease. For each country, we assessed HPV vaccination of girls before age 12 followed by screening with HPV DNA testing once, twice, or three times per lifetime (at ages 35, 40, 45). For women over age 30, we assessed only screening (with HPV DNA testing up to three times per lifetime or VIA at age 35). Assuming no waning immunity, mean reduction in lifetime cancer risk associated with vaccination ranged from 36 to 45%, and vaccination followed by screening once per lifetime at age 35 with HPV DNA testing ranged from 43 to 51%. For both younger and older women, the most effective screening strategy was HPV DNA testing three times per lifetime. Provided the cost per vaccinated girl was less than I$10 (I$2 per dose), vaccination had an incremental cost-effectiveness ratio [I$ (international dollars)/year of life saved (YLS)] less than the country-specific per capita GDP, a commonly cited heuristic for "very cost-effective" interventions. If the cost per vaccinated girl was between I$10 (I$2 per dose) and I$25 (I$5 per dose), vaccination followed by HPV DNA testing would save the most lives and would be considered good value for public health dollars. These results should be used to catalyze design and evaluation of HPV vaccine delivery and screening programs, and contribute to a dialogue on financing HPV vaccination in poor countries.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.